Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Gastric Cancer-Pipeline Review, H1 2015

Gastric Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Gastric Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Gastric Cancer-Pipeline Review, H1 2015', provides an overview of the Gastric Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastric Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Gastric Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Gastric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Gastric Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Gastric Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Gastric Cancer Overview 8

Therapeutics Development 9

Gastric Cancer-Therapeutics under Development by Companies 11

Gastric Cancer-Therapeutics under Investigation by Universities/Institutes 21

Gastric Cancer-Pipeline Products Glance 23

Gastric Cancer-Products under Development by Companies 27

Gastric Cancer-Products under Investigation by Universities/Institutes 39

Gastric Cancer-Companies Involved in Therapeutics Development 40

Gastric Cancer-Therapeutics Assessment 144

Drug Profiles 164

Gastric Cancer-Recent Pipeline Updates 456

Gastric Cancer-Dormant Projects 595

Gastric Cancer-Discontinued Products 603

Gastric Cancer-Product Development Milestones 606

Appendix 613

List of Tables

Number of Products under Development for Gastric Cancer, H1 2015 28

Number of Products under Development for Gastric Cancer-Comparative Analysis, H1 2015 29

Number of Products under Development by Companies, H1 2015 31

Number of Products under Development by Companies, H1 2015 (Contd..1) 32

Number of Products under Development by Companies, H1 2015 (Contd..2) 33

Number of Products under Development by Companies, H1 2015 (Contd..3) 34

Number of Products under Development by Companies, H1 2015 (Contd..4) 35

Number of Products under Development by Companies, H1 2015 (Contd..5) 36

Number of Products under Development by Companies, H1 2015 (Contd..6) 37

Number of Products under Development by Companies, H1 2015 (Contd..7) 38

Number of Products under Development by Companies, H1 2015 (Contd..8) 39

Number of Products under Investigation by Universities/Institutes, H1 2015 41

Comparative Analysis by Late Stage Development, H1 2015 42

Comparative Analysis by Clinical Stage Development, H1 2015 43

Comparative Analysis by Early Stage Development, H1 2015 44

Comparative Analysis by Unknown Stage Development, H1 2015 45

Products under Development by Companies, H1 2015 46

Products under Development by Companies, H1 2015 (Contd..1) 47

Products under Development by Companies, H1 2015 (Contd..2) 48

Products under Development by Companies, H1 2015 (Contd..3) 49

Products under Development by Companies, H1 2015 (Contd..4) 50

Products under Development by Companies, H1 2015 (Contd..5) 51

Products under Development by Companies, H1 2015 (Contd..6) 52

Products under Development by Companies, H1 2015 (Contd..7) 53

Products under Development by Companies, H1 2015 (Contd..8) 54

Products under Development by Companies, H1 2015 (Contd..9) 55

Products under Development by Companies, H1 2015 (Contd..10) 56

Products under Development by Companies, H1 2015 (Contd..11) 57

Products under Investigation by Universities/Institutes, H1 2015 58

Gastric Cancer-Pipeline by AB Science, H1 2015 59

Gastric Cancer-Pipeline by AbbVie Inc., H1 2015 60

Gastric Cancer-Pipeline by AbGenomics International, Inc., H1 2015 61

Gastric Cancer-Pipeline by Advaxis, Inc., H1 2015 62

Gastric Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 63

Gastric Cancer-Pipeline by Ambrx, Inc., H1 2015 64

Gastric Cancer-Pipeline by Amgen Inc., H1 2015 65

Gastric Cancer-Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 66

Gastric Cancer-Pipeline by Astellas Pharma Inc., H1 2015 67

Gastric Cancer-Pipeline by AstraZeneca PLC, H1 2015 68

Gastric Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 69

Gastric Cancer-Pipeline by Avipep Pty Ltd, H1 2015 70

Gastric Cancer-Pipeline by Azaya Therapeutics Incorporated, H1 2015 71

Gastric Cancer-Pipeline by Basilea Pharmaceutica AG, H1 2015 72

Gastric Cancer-Pipeline by Bayer AG, H1 2015 73

Gastric Cancer-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 74

Gastric Cancer-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 75

Gastric Cancer-Pipeline by Biotecnol, Inc., H1 2015 76

Gastric Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 77

Gastric Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 78

Gastric Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 79

Gastric Cancer-Pipeline by cCAM Biotherapeutics Ltd., H1 2015 80

Gastric Cancer-Pipeline by Celgene Corporation, H1 2015 81

Gastric Cancer-Pipeline by Cellectar Biosciences, Inc., H1 2015 82

Gastric Cancer-Pipeline by Celltrion, Inc., H1 2015 83

Gastric Cancer-Pipeline by Celon Pharma Sp. z o.o., H1 2015 84

Gastric Cancer-Pipeline by Cerulean Pharma, Inc., H1 2015 85

Gastric Cancer-Pipeline by Chipscreen Biosciences Ltd, H1 2015 86

Gastric Cancer-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 87

Gastric Cancer-Pipeline by Covagen AG, H1 2015 88

Gastric Cancer-Pipeline by DAE HWA Pharmaceutical Co., Ltd., H1 2015 89

Gastric Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 90

Gastric Cancer-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 91

Gastric Cancer-Pipeline by DiaMedica Inc., H1 2015 92

Gastric Cancer-Pipeline by Dong-A Socio Group, H1 2015 93

Gastric Cancer-Pipeline by Eddingpharm, H1 2015 94

Gastric Cancer-Pipeline by Eli Lilly and Company, H1 2015 95

Gastric Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 96

Gastric Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 97

Gastric Cancer-Pipeline by Exelixis, Inc., H1 2015 98

Gastric Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 99

Gastric Cancer-Pipeline by Five Prime Therapeutics, Inc., H1 2015 100

Gastric Cancer-Pipeline by Galaxy Biotech, LLC, H1 2015 101

Gastric Cancer-Pipeline by Galena Biopharma, Inc., H1 2015 102

Gastric Cancer-Pipeline by Genentech, Inc., H1 2015 103

Gastric Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 104

Gastric Cancer-Pipeline by GlycoNex Inc., H1 2015 105

Gastric Cancer-Pipeline by Glycotope GmbH, H1 2015 106

Gastric Cancer-Pipeline by Green Cross Corporation, H1 2015 107

Gastric Cancer-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 108

Gastric Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 109

Gastric Cancer-Pipeline by ImmunoGen, Inc., H1 2015 110

Gastric Cancer-Pipeline by Immunomedics, Inc., H1 2015 111

Gastric Cancer-Pipeline by Imugene Limited, H1 2015 112

Gastric Cancer-Pipeline by Incuron, LLC, H1 2015 113

Gastric Cancer-Pipeline by Incyte Corporation, H1 2015 114

Gastric Cancer-Pipeline by INSYS Therapeutics, Inc., H1 2015 115

Gastric Cancer-Pipeline by Intezyne, Inc, H1 2015 116

Gastric Cancer-Pipeline by ISU ABXIS Co.,Ltd., H1 2015 117

Gastric Cancer-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 118

Gastric Cancer-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015 119

Gastric Cancer-Pipeline by Kadmon Corporation, LLC, H1 2015 120

Gastric Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 121

Gastric Cancer-Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 122

Gastric Cancer-Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 123

Gastric Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 124

Gastric Cancer-Pipeline by Les Laboratoires Servier SAS, H1 2015 125

Gastric Cancer-Pipeline by MacroGenics, Inc., H1 2015 126

Gastric Cancer-Pipeline by Mebiopharm Co., Ltd., H1 2015 127

Gastric Cancer-Pipeline by Merck & Co., Inc., H1 2015 128

Gastric Cancer-Pipeline by Merck KGaA, H1 2015 129

Gastric Cancer-Pipeline by Mersana Therapeutics, Inc., H1 2015 130

Gastric Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 131

Gastric Cancer-Pipeline by Molecular Targeting Technologies, Inc., H1 2015 132

Gastric Cancer-Pipeline by MSM Protein Technologies, Inc., H1 2015 133

Gastric Cancer-Pipeline by NanoCarrier Co., Ltd., H1 2015 134

Gastric Cancer-Pipeline by NeoPharm Co., Ltd., H1 2015 135

Gastric Cancer-Pipeline by Novartis AG, H1 2015 136

Gastric Cancer-Pipeline by Omnitura Therapeutics Inc., H1 2015 137

Gastric Cancer-Pipeline by OncoTherapy Science, Inc., H1 2015 138

Gastric Cancer-Pipeline by Oncothyreon Inc., H1 2015 139

Gastric Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 140

Gastric Cancer-Pipeline by Panacea Biotec Limited, H1 2015 141

Gastric Cancer-Pipeline by Patrys Limited, H1 2015 142

Gastric Cancer-Pipeline by Pfizer Inc., H1 2015 143

Gastric Cancer-Pipeline by Pharmacyclics, Inc., H1 2015 144

Gastric Cancer-Pipeline by Priaxon AG, H1 2015 145

Gastric Cancer-Pipeline by Regulon Inc., H1 2015 146

Gastric Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 147

Gastric Cancer-Pipeline by Richter Gedeon Nyrt., H1 2015 148

Gastric Cancer-Pipeline by Sanofi, H1 2015 149

Gastric Cancer-Pipeline by Sareum Holdings plc, H1 2015 150

Gastric Cancer-Pipeline by SentoClone International AB, H1 2015 151

Gastric Cancer-Pipeline by Sequella, Inc., H1 2015 152

Gastric Cancer-Pipeline by Siena Biotech S.p.A., H1 2015 153

Gastric Cancer-Pipeline by Sorrento Therapeutics, Inc., H1 2015 154

Gastric Cancer-Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 155

Gastric Cancer-Pipeline by Supratek Pharma Inc., H1 2015 156

Gastric Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 157

Gastric Cancer-Pipeline by Synthon Holdings BV, H1 2015 158

Gastric Cancer-Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 159

Gastric Cancer-Pipeline by Tesaro, Inc., H1 2015 160

Gastric Cancer-Pipeline by Vaxon Biotech, H1 2015 161

Gastric Cancer-Pipeline by Zymeworks Inc., H1 2015 162

Assessment by Monotherapy Products, H1 2015 163

Assessment by Combination Products, H1 2015 164

Number of Products by Stage and Target, H1 2015 166

Number of Products by Stage and Mechanism of Action, H1 2015 174

Number of Products by Stage and Route of Administration, H1 2015 180

Number of Products by Stage and Molecule Type, H1 2015 182

Gastric Cancer Therapeutics-Recent Pipeline Updates, H1 2015 475

Gastric Cancer-Dormant Projects, H1 2015 614

Gastric Cancer-Dormant Projects (Contd..1), H1 2015 615

Gastric Cancer-Dormant Projects (Contd..2), H1 2015 616

Gastric Cancer-Dormant Projects (Contd..3), H1 2015 617

Gastric Cancer-Dormant Projects (Contd..4), H1 2015 618

Gastric Cancer-Dormant Projects (Contd..5), H1 2015 619

Gastric Cancer-Dormant Projects (Contd..6), H1 2015 620

Gastric Cancer-Dormant Projects (Contd..7), H1 2015 621

Gastric Cancer-Discontinued Products, H1 2015 622

Gastric Cancer-Discontinued Products (Contd..1), H1 2015 623

Gastric Cancer-Discontinued Products (Contd..2), H1 2015 624

List of Figures

Number of Products under Development for Gastric Cancer, H1 2015 28

Number of Products under Development for Gastric Cancer-Comparative Analysis, H1 2015 29

Number of Products under Development by Companies, H1 2015 30

Number of Products under Investigation by Universities/Institutes, H1 2015 40

Comparative Analysis by Late Stage Development, H1 2015 42

Comparative Analysis by Clinical Stage Development, H1 2015 43

Comparative Analysis by Early Stage Products, H1 2015 44

Assessment by Monotherapy Products, H1 2015 163

Assessment by Combination Products, H1 2015 164

Number of Products by Stage and Top 10 Targets, H1 2015 165

Number of Products by Top 10 Mechanism of Actions, H1 2015 173

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 173

Number of Products by Top 10 Routes of Administration, H1 2015 179

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 179

Number of Products by Top 10 Molecule Types, H1 2015 181

Number of Products by Stage and Top 10 Molecule Types, H1 2015 181

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AbbVie Inc.

AbGenomics International, Inc.

Advaxis, Inc.

Advenchen Laboratories, LLC

Ambrx, Inc.

Amgen Inc.

Aslan Pharmaceuticals Pte. Ltd.

Astellas Pharma Inc.

AstraZeneca PLC

AVEO Pharmaceuticals, Inc.

Avipep Pty Ltd

Azaya Therapeutics Incorporated

Basilea Pharmaceutica AG

Bayer AG

Bellicum Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc.

Biotecnol, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

cCAM Biotherapeutics Ltd.

Celgene Corporation

Cellectar Biosciences, Inc.

Celltrion, Inc.

Celon Pharma Sp. z o.o.

Cerulean Pharma, Inc.

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co., Ltd.

Covagen AG

DAE HWA Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Deciphera Pharmaceuticals, LLC

DiaMedica Inc.

Dong-A Socio Group

Eddingpharm

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Esperance Pharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Galaxy Biotech, LLC

Galena Biopharma, Inc.

Genentech, Inc.

GlaxoSmithKline plc

GlycoNex Inc.

Glycotope GmbH

Green Cross Corporation

Hanmi Pharmaceuticals, Co. Ltd.

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Imugene Limited

Incuron, LLC

Incyte Corporation

INSYS Therapeutics, Inc.

Intezyne, Inc

ISU ABXIS Co.,Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Kadmon Corporation, LLC

Karyopharm Therapeutics, Inc.

Kinex Pharmaceuticals, LLC

Kuhnil Pharmaceutical Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

MacroGenics, Inc.

Mebiopharm Co., Ltd.

Merck & Co., Inc.

Merck KGaA

Mersana Therapeutics, Inc.

Millennium Pharmaceuticals, Inc.

Molecular Targeting Technologies, Inc.

MSM Protein Technologies, Inc.

NanoCarrier Co., Ltd.

NeoPharm Co., Ltd.

Novartis AG

Omnitura Therapeutics Inc.

OncoTherapy Science, Inc.

Oncothyreon Inc.

Ono Pharmaceutical Co., Ltd.

Panacea Biotec Limited

Patrys Limited

Pfizer Inc.

Pharmacyclics, Inc.

Priaxon AG

Regulon Inc.

Rexahn Pharmaceuticals, Inc.

Richter Gedeon Nyrt.

Sanofi

Sareum Holdings plc

SentoClone International AB

Sequella, Inc.

Siena Biotech S.p.A.

Sorrento Therapeutics, Inc.

Sunesis Pharmaceuticals, Inc.

Supratek Pharma Inc.

Synta Pharmaceuticals Corp.

Synthon Holdings BV

Taiho Pharmaceutical Co., Ltd.

Tesaro, Inc.

Vaxon Biotech

Zymeworks Inc.

Gastric Cancer Therapeutic Products under Development, Key Players in Gastric Cancer Therapeutics, Gastric Cancer Pipeline Overview, Gastric Cancer Pipeline, Gastric Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com